Goldman Sachs
Adaptive Bio Initiates Strategic Review, Considers Separation of MRD, Immune Medicine Businesses
Premium
While reporting its Q3 earnings results, Adaptive said it hired Goldman Sachs to perform "a review of strategic alternatives" for its MRD and immune medicine businesses.
Myriad Genetics to Raise $110M in Public Stock Offering
The Salt Lake City-based genetic testing and precision medicine company is offering 6,470,588 shares of its common stock at a public offering price of $17 per share.
Pacific Biosciences to Raise $175M in Public Stock Offering
The company is selling 17.5 million shares of its common stock at a price of $10 per share in the offering, which is expected to close Jan. 27.
PerkinElmer Reaches Deal for $1.5B Credit Facility
The agreement is for a new credit facility, which replaces one from 2019 that provided for a $1 billion unsecured revolving credit facility.
PerkinElmer Enters $500M Credit Facility
The proceeds will be used to pay, in part, PerkinElmer's $5.25B acquisition of BioLegend, announced last month.
May 24, 2021
Singular Genomics Ups IPO Target to $187M
Dec 2, 2020
Twist Bioscience Proposes $250M Public Offering
Jul 29, 2020
Sema4 Raises $121M in Series C Financing Round
Aug 20, 2019
10x Genomics Files for $100M IPO
Dec 18, 2014
Goldman Sachs Downgrades Qiagen, Bruker
Jun 23, 2014
Goldman Sachs Reinstates Neutral Rating for Agilent
Mar 28, 2013